Cargando…
MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity
MLL-fusions represent a large group of leukemia drivers, whose diversity originates from the vast molecular heterogeneity of C-terminal fusion partners of MLL. While studies of selected MLL-fusions have revealed critical molecular pathways, unifying mechanisms across all MLL-fusions remain poorly un...
Autores principales: | Skucha, Anna, Ebner, Jessica, Schmöllerl, Johannes, Roth, Mareike, Eder, Thomas, César-Razquin, Adrián, Stukalov, Alexey, Vittori, Sarah, Muhar, Matthias, Lu, Bin, Aichinger, Martin, Jude, Julian, Müller, André C., Győrffy, Balázs, Vakoc, Christopher R., Valent, Peter, Bennett, Keiryn L., Zuber, Johannes, Superti-Furga, Giulio, Grebien, Florian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5959866/ https://www.ncbi.nlm.nih.gov/pubmed/29777171 http://dx.doi.org/10.1038/s41467-018-04329-y |
Ejemplares similares
-
Roles of SETD2 in Leukemia—Transcription, DNA-Damage, and Beyond
por: Skucha, Anna, et al.
Publicado: (2019) -
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia
por: Grebien, Florian, et al.
Publicado: (2015) -
Affinity Purification Strategies for Proteomic Analysis
of Transcription Factor Complexes
por: Giambruno, Roberto, et al.
Publicado: (2013) -
CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex
por: Schmidt, Luisa, et al.
Publicado: (2019) -
SETD2 maintains nuclear lamina stability to safeguard the genome
por: Khan, Abid, et al.
Publicado: (2023)